Faculty Summaries
Efrat Dotan, MD
Efrat Dotan, MD
Assistant Professor
Efrat.Dotan@fccc.edu
Office Phone: 215-728-2985
Fax: 215-728-3639
Office: C303
Research Interests

With the aging of the general population, the number of older adults with cancer continues to rise. Treatment of elderly cancer patients is challenging due to multiple co-morbidities, increased risk of frailty, poor tolerance to therapy, and need for strong social support. My main research focus is in management and improvement of outcomes of elderly patients with gastrointestinal malignancies. My research aims to identify new biomarkers of aging that could be used for non invasive assessment of patient’s biologic rather than chronologic age. These biomarkers could assist the oncologist in prediction of chemotherapy tolerance among older patients. In addition, as the leader of the geriatric oncology clinical and research team we continue to study treatment outcomes of older adults with various cancers, and hope to gain understanding of improvements needed in the management of this patient population.

As a medical oncologist treating patients with gastrointestinal malignancies, I encounter the need for new treatment approaches on a daily basis. As such, I am leading multiple clinical trials which are evaluating new and improved therapies for gastrointestinal malignancies. These include novel agents for treatment of refractory colon cancers, and liver directed therapy for colon cancer metastases.

Description of research projects
Selected Publications

Fox Chase Programs

  1. Namrata Vijayvergia, Efrat Dotan, Karthik Devarajan, Kamel Hatahet, Farah Rahman, Steven J. Cohen. Differences in patterns of care and outcomes of elderly versus younger metastatic pancreatic cancer (mPC) patients. J Clin Oncol 31, 2013 (suppl; abstr 9546).
  2. Efrat Dotan, Tianyu LI, Michael J. Hall, Neal J. Meropol, Robert J. Beck, Yu-Ning Wong. De-adoption of epidermal growth factor receptor (EGFR) inhibitors following recommendations for KRAS testing to guide treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 30, 2012 (suppl; abstr e14021)
  3. Efrat Dotan, Neal Meropol, Fang Zhu, Frank Zambito, Betsy Bove, Kathy Q. Cai, Andrew K. Godwin, Erica A. Golemis, Igor Astsaturov and  Steven J. Cohen. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55.
  4. Efrat Dotan, Neal J. Meropol, Barbara Burtness, Crystal S, Denlinger, James Lee, David Mintzer, Fang Zhu, Karen Ruth, Holly Tuttle, Judi Sylvester, and Steven J. Cohen. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer.  A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC3400721
  5. Efrat Dotan, Ilene Brown, Arti Hurria, Crystal Denlinger: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24.
  6. Efrat Dotan, Steven, J. Cohen. Challenges in the management of stage II colon cancer. Seminars in Oncology Aug 2011; 38(4): 511-20.
All publications